Substance · official US FDA label
Trinitrine (nitroglycerin)
17 medicines listed on Vimpia contain it, alone or combined. Below, the official US FDA label for nitroglycerin, unchanged.
Want to buy it?
Trouver shows the pharmacies near you that have it right now, and their prices. The reservation pages are in French.
This is a US label.
The official US FDA label for nitroglycerin, effective September 9, 2026, describes products sold in the United States. The medicine sold in DR Congo may differ in strength, form or approved uses: ask a pharmacist or a doctor.
Official US FDA label for nitroglycerin
Data provided by the U.S. Food and Drug Administration (openFDA), unchanged. The full label on DailyMed.
Uses
1 INDICATIONS AND USAGE Nitroglycerin sublingual tablets are indicated for the acute relief of an attack or acute prophylaxis of angina pectoris due to coronary artery disease. Nitroglycerin sublingual tablets are nitrate vasodilator indicated for relief of an attack or prophylaxis of angina pectoris due to coronary artery disease. (1)
Dosage
US dosage, for products sold in the United States. For a medicine bought in DR Congo, follow its box, its leaflet or your pharmacist.
2 DOSAGE AND ADMINISTRATION Administer one tablet under the tongue or in the buccal pouch at the first sign of an acute anginal attack. Allow tablet to dissolve without swallowing. One additional tablet may be administered every 5 minutes until relief is obtained. No more than three tablets are recommended within a 15-minute period. If the pain persists after a total of 3 tablets in a 15-minute period, or if the pain is different than is typically experienced, seek prompt medical attention. Nitroglycerin sublingual tablets may be used prophylactically 5 minutes to 10 minutes prior to engaging in activities that might precipitate an acute attack. For patients with xerostomia, a small sip of water prior to placing the tablet under the tongue may help maintain mucosal hydration and aid dissolution of the tablet. Administer nitroglycerin sublingual tablets at rest, preferably in the sitting position. At the onset of an attack, administer one tablet under the tongue or buccal pouch. One additional tablet may be administered every 5 minutes as needed. No more than 3 total tablets are recommended within a 15 minute period. (2) If chest pain persists after three tablets, seek prompt medical attention. (2) May be used prophylactically 5 to 10 minutes prior to engaging in activities that might precipitate an acute attack. (2)
Warnings and precautions
5 WARNINGS AND PRECAUTIONS Tolerance: Excessive use may lead to tolerance. (5.1) Hypotension: Severe hypotension may occur. (5.2) 5.1 Tolerance Excessive use may lead to the development of tolerance. Only the smallest dose required for effective relief of the acute angina attack should be used. A decrease in therapeutic effect of sublingual nitroglycerin may result from use of long-acting nitrates. 5.2 Hypotension Severe hypotension, particularly with upright posture, may occur with small doses of nitroglycerin particularly in patients with constrictive pericarditis, aortic or mitral stenosis, patients who may be volume- depleted, or are already hypotensive. Hypotension induced by nitroglycerin may be accompanied by paradoxical bradycardia and increased angina pectoris. Symptoms of severe hypotension (nausea, vomiting, weakness, pallor, perspiration and collapse/syncope) may occur even with therapeutic doses. 5.3 Hypertrophic Obstructive Cardiomyopathy Nitrate therapy may aggravate the angina caused by hypertrophic cardiomyopathy. 5.4 Headache Nitroglycerin produces dose-related headaches, especially at the start of nitroglycerin therapy, which may be severe and persist but usually subside with continued use.
Side effects
6 ADVERSE REACTIONS The following adverse reactions are discussed in more detail elsewhere in the label: Hypotension [see Warnings and Precautions (5.2)] Headache [see Warnings and Precautions (5.4)] Hypersensitivity [see Contraindications (4.4)] Vertigo, dizziness, weakness, palpitation, and other manifestations of postural hypotension may develop occasionally, particularly in erect, immobile patients. Marked sensitivity to the hypotensive effects of nitrates (manifested by nausea, vomiting, weakness, diaphoresis, pallor, and collapse) may occur at therapeutic doses. Syncope due to nitrate vasodilatation has been reported. Flushing, drug rash, and exfoliative dermatitis have been reported in patients receiving nitrate therapy. Most common adverse reactions occurring at a frequency greater than 2% are headache, dizziness and paresthesia. (6) To report SUSPECTED ADVERSE REACTIONS, contact Northstar Rx LLC at 1-800-206-7821 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Medicines that contain it
Names as they are sold. A medicine without an English page links to its French page.
- DISCOTRINE 10 mg/24 heures, dispositif transdermique
- DISCOTRINE 15 mg/24 heures, dispositif transdermique
- DISCOTRINE 5 mg/24 heures, dispositif transdermique
- EPINITRIL 10 mg/24 heures, dispositif transdermique
- EPINITRIL 15 mg/24 heures, dispositif transdermique
- EPINITRIL 5 mg/24 heures, dispositif transdermique
- NATISPRAY 0,15 mg/dose, solution pour pulvérisation buccale
- NATISPRAY 0,30 mg/dose, solution pour pulvérisation buccale
- NITRIDERM TTS 10 mg/24 h, dispositif transdermique
- NITRIDERM TTS 15 mg/24 h, dispositif transdermique
- NITRIDERM TTS 5 mg/24 h, dispositif transdermique
- NITRONAL 1 mg/ml, solution pour perfusion
- TRINIPATCH 10 mg/24 heures, dispositif transdermique (44,8 mg / 14 cm²)
- TRINIPATCH 15 mg/24 heures, dispositif transdermique (67,2 mg / 21 cm²)
- TRINIPATCH 5 mg/24 heures, dispositif transdermique (22,4 mg / 7 cm²)
- TRINITRINE VIATRIS 10 mg/24 heures, dispositif transdermique
- TRINITRINE VIATRIS 5 mg/24 heures, dispositif transdermique
Sources
- ●Labels: U.S. Food and Drug Administration, openFDA (public domain). Data provided by the U.S. Food and Drug Administration (openFDA), unchanged. DailyMed.
- ●English names of substances: RxNorm, U.S. National Library of Medicine.
- ●Marketing authorizations: register of the ACOREP, DR Congo.
- ●Essential medicines: national list of essential medicines of DR Congo (LNME).
- ●Composition: public medicines database of France (BDPM), ANSM, open licence.
Public information, for reference only: it does not replace the advice of a pharmacist or a doctor. Vimpia writes nothing about how to use a medicine and translates nothing: the label is the US FDA's, unchanged; names, composition and authorizations come from the official sources above.